

APPLICATION GUIDE Human GFAP ELISA Kit

Catalog No. EA200012

For quantitative detection of human GFAP in serum, plasma and other biological fluids

FOR RESEARCH USE ONLY NOT FOR USE IN DIAGNOSTIC PROCEDURE



Principle of the Assay

Glial fibrillary acidic protein (GFAP) is a type III intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS), including astrocytes and ependymal cells during development. GFAP has also been found to be expressed in glomeruli and peritubular fibroblasts, Leydig cells of the testis, keratinocytes, osteocytes and chondrocytes. It has been shown to be important in the pathogenesis of Alexander disease and in repair after CNS injury. Decreases in GFAP expression have been reported in Down's syndrome, schizophrenia, bipolar disorder and depression. GFAP levels are already used as a marker for the activation of astrocytes (AS) following injury or stress in the CNS. Serum GFAP shows promise as a biomarker of disease severity in frontotemporal lobar degeneration (FTLD), and might be a suitable multiple sclerosis progression biomarker. In addition, GFAP has been used as a classical marker of astrocytoma and a diagnostic biomarker for glioblastoma multiforme (GBM).

This sandwich ELISA is used to measure human GFAP in serum, plasma and other biological fluids. Microtitration wells coated with anti-human GFAP capture antibody are exposed to test specimens. The GFAP antigen in the specimen is specifically captured onto the immobilized antibody during specimen incubation. The captured GFAP antigen is then reacted with HRP conjugated human GFAP detection antibody. After wash, specifically bound enzyme conjugate is detected by reaction with the Substrate Solution, tetramethylbenzidine (TMB). The assay is measured spectrophotometrically to indicate the level of GFAP present in a sample.

Kit Presentation

Materials Supplied

The reagents supplied in this pack are for Research Use Only.

Description	Quantity
GFAP Antibody Coated 96-well Plate in foil pouch with desiccant	1
Recombinant Human GFAP Standard (2.5µg/mL)	100 µL
HRP Conjugated GFAP Detection Antibody (100x)	120 µL
Assay Buffer	60 mL
Substrate Solution (TMB)	12 mL
Stop Solution (1N HCI)	12 mL
Wash Buffer (20x)	60 mL
Plate Sealer	2



Additional Requirements for Manual Processing

- 1. Horizontal orbital plate shaker capable of maintaining a speed of 450±50 rpm.
- 2. Disposable pipet tips to deliver volumes of 5 μ L, 10 μ L, 25 μ L, 100 μ L and 200 μ L (multichannel pipette preferred for dispensing reagents into microtiter plates).
- 3. Distilled or deionized water.
- 4. Clean, disposable plastic/glass test tubes, approximate capacities 5mL and 10mL.
- 5. Range of standard, clean volumetric laboratory glassware consisting of, at least, 15 mL and 100 mL beakers, 1 L graduated cylinder, 1 mL, 5 mL, and 10 mL pipettes.
- 6. Absorbent paper towels.
- 7. Automatic microplate washer or laboratory wash bottle.
- 8. Microplate reader with 450nm filter.
- 9. Latex gloves, safety glasses and other appropriate protective garments.
- 10. Biohazard waste containers.
- 11. Safety pipetting devices for 1 mL or larger pipettes.
- 12. Timer.

Storage and Stability

All reagents should be stored at 2-8°C and should not be used beyond the expiration date on the label. Once opened, microtitration strips may be stored at 2-8°C until the expiration date on the label, provided that desiccated conditions are maintained. Unused strips should be returned to their original foil pouch along with the sachet of desiccant. Secure open foil pouch using zip top before storage. The working strength Wash Buffer should not be stored for longer than 3 weeks at 2-8°C. It is recommended that Wash buffer be freshly diluted before each assay. If the working strength buffer becomes visibly cloudy or develops precipitate during the 3 weeks, do not use it.

Indications of Deterioration

The human GFAP Assay kit may be considered to have deteriorated if:

1. Reagents becoming visibly cloudy or develop precipitate. Note: Concentrated Wash buffer, when cold, normally develops crystalline precipitates, which re-dissolve on heating at 37°C.

2. The Substrate Solution turns dark blue. This is likely to be caused by chemical contamination of the Substrate Solution.

Warnings and Precaution

Safety

1. The reagents supplied in this kit are for *Research use only*.

2. Caution: All blood products should be treated as potentially infectious.

Essential precautions can be summarized as follows:

>do not pipette by mouth.



>Wear disposable gloves during all specimen and assay manipulations.

>Avoid use of sharp or pointed liquid handling devices, which may puncture skin.

>Do not smoke, eat or drink in the laboratory work area.

>Avoid splashing of liquid specimens and reagents and the formation of aerosols.

>Wash hands thoroughly on completion of a manipulation.

>The Centers for Disease Control & Prevention and the National Institutes of Health recommend that potentially infectious agents be handled at Biosafety Level 2.

3. The kit contains reagent systems, which are optimized and balanced for each kit lot. Do not interchange reagents from kits with different lot numbers. Do not interchange vial caps or stoppers either within or between kits.

4. The Substrate Solution and Stop Solution in this kit contain ingredients that can irritate the skin and cause eye damage. Handle them with care and wear suitable protective clothing and eye/face protection. In case of contact with skin or eyes, immediately flush the affected area with plenty of water. For eyes, obtain medical attention.

5. Disposal or decontamination of fluid in the waste reservoir from either the plate washer or trap for vacuum line in the manual system should be in accordance with guidelines set forth in the Department of Labor, Occupational Safety and Health Administration, occupational exposure to blood-borne pathogens; final rule (29 CFR 1910,1030) FEDERAL REGISTER, pp. 64176-84177,12/6/91.

Technical Suggestions

- 1. This kit should be used in strict accordance with the instructions in the Package Insert.
- 2. Do not use the kit after the expiration date printed on the outer carton label.
- 3. Do not cross contaminate reagents.
- 4. To ensure accurate results and avoid cross-contamination, use proper adhesive plate sealers during incubation steps, and change pipette tips when adding each standard and sample. Multi-channel pipettes are recommended for large assays. Always use fresh pipette tips when drawing from stock reagent bottles.
- 5. All reagents should be added to the plate in the same order.
- 6. Protect Substrate Solution from light.
- 7. If the Stop Solution does not mix thoroughly with the Substrate Solution, the color in the wells may appear green after adding stop solution. Gently tap the plate or pipette up and down to mix until the color in the wells change to yellow (avoid bubbles during this step).
- 8. Always use clean, preferably disposable, glassware for all reagent preparation.
- 9. Allow foil bags to warm to room temperature before opening. This avoids condensation on the inner surface of the bag, which may contribute to a deterioration of coated strips intended for future use.



- 10. Reagents should be dispensed with the tip of the micropipettes touching the side of the well at a point about mid-section. Follow manufacturer's recommendations for automatic processors.
- 11. Always keep the upper surface of the microtitration strips free from excess fluid droplets. Reagents and buffer over-spill should be blotted dry on completion of the manipulation.
- 12. Do not allow the wells to completely dry during an assay.
- 13. Automatic or semi-automatic EIA processors or liquid handling systems should be qualified specifically for use with the assay by demonstration of equivalence to the manual processing methods.
- 14. Consistent with good laboratory practice, it is recommended that all pipetting devices (manual or automatic), timers and thermometers are regularly calibrated according to the manufacturer's instructions.
- 15. Care must be taken to ensure that specimens are dispensed correctly to each test well. If a specimen is inadvertently not added to a well, the result for that well will be non-reactive, regardless of the actual result of the specimen.

Method of Use

Specimen Collection and Storage

The Human GFAP ELISA is intended for use with serum, plasma and other biological fluids. The specimen should be tested as soon as possible. However, if the specimen needs storage, the specimens should be stored frozen at -20°C or below. Do not use self-defrosting freezers. Specimens that have been frozen and thawed should be thoroughly mixed before testing.

Serum: Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Plasma: Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Urine: Collect the first urine of the day (mid-stream) as eptically. Centrifuge to remove particulate matter. Assay immediately or aliquot and store at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Cell culture supernatants and other biological fluids: Remove particulates by centrifugation and assay immediately or aliquot and store samples at \leq -20 °C. Avoid repeated freeze-thaw cycles.

Rinse Cycle

Efficient rinsing to remove un-complexed components is a fundamental requirement of enzyme immunoassay procedures. Automatic plate washers may be used provided they meet the following criteria: 1. All wells are completely aspirated. 2. All wells are filled to



the rim (about 300 μ L) during the rinse cycle. 3. Wash buffer is dispensed at a good flow rate. 4. The microtitration plate washer must be well maintained to prevent contamination from previous use. Manufacturer's cleaning procedures must be followed diligently

For the rinse cycle, the machine should be set to four consecutive washes. On completion of the cycle, invert the microtitration plate and tap firmly on absorbent paper towels. Check for any residual Wash buffer in the wells and blot dry the upper surface of the wells with a paper towel.

Alternatively, the following manual system may be employed:

1. Discard or aspirate well contents using a vacuum line fitted with a trap.

2. Fill all wells to the brim with wash buffer dispensed from a squeeze-type laboratory wash bottle.

- 3. Discard or aspirate fluids.
- 4. Repeat steps 2 and 3, three times.
- 5. Invert the microtitration plate and tap firmly on absorbent paper towels.

Preparation for the Assay

1. Standard preparation

Prepare protein standard by diluting 10μ L of standard stock into 490 μ L (1:50 dilution) of assay buffer. This will give a final concentration of 50 ng/mL as shown in Table 1

2. Sample preparation: GFAP concentration must be estimated prior to performing the full experiment by testing a serially diluted representative sample using assay buffer. Select an optimal dilution level such that the final target protein concentration falls near the middle of the assay linear dynamic range. Or refer to published literature for expected concentrations and derive the optimal dilution level based on the expected dynamic range of the kit. For normal plasma samples, no dilution is needed; for normal serum samples, a 5-fold dilution is suggested.

3. *HRP Conjugated GFAP Detection Antibody preparation*: dilute the concentrated HRP antibody conjugate 1:100 using assay buffer.

4. Wash buffer preparation

Prepare working-strength Wash buffer by diluting 1 part concentrate with 19 parts of distilled or de-ionized water. If a kit is likely to be utilized over a period in excess of 4 weeks, then it is recommended that only enough stock concentrate be diluted sufficient for immediate needs.

Quantitative Assay Procedure

To test quantitatively, a standard curve should be prepared using assay diluent as shown in the table below. Each standard should be run in duplicate.



Standard Number	Concentration of GFAP (ng/mL)	GFAP Standard (µL)	Assay Buffer (µL)
1	50	10	490
2	25	250 of #1	250
3	12.5	250 of #2	250
4	6.25	250 of #3	250
5	3.125	250 of #4	250
6	1.5625	250 of #5	250
7	0.78125	250 of #6	250
8	0		250

Table 1: Human GFAP Quantitative Standard Curve Generation

Assay Procedure

1. Allow all reagents to reach room temperature (18-25°C).

2. Select sufficient microtitration well strips to accommodate all test specimens, controls and reagent blank. Fit the strips into the holding frame. Label wells according to specimen identity using the letter/number cross-reference system molded into the plastic frame.

3. Dispense 100 μ L of each standard and sample into appropriate wells. Note: All standards and samples should be tested in duplicate. Note: Depending on the GFAP concentration of your sample, dilution using assay buffer may be needed.

4. Incubate for 2 hours at room temperature with moderate shaking (450±50rpm) on a horizontal orbital plate shaker.

5. Wash the microtitration plate 4 times as described in the Rinse Cycle section.

6. Pipette 100 μ L of 1x HRP conjugated detection antibody into each well and incubate for 1 hour at room temperature with moderate shaking (450±50rpm) on a horizontal orbital plate shaker.

7. Wash the microtitration plate 4 times as described in the Rinse Cycle section.

8. Dispense 100 μ L Substrate Solution into each well. A multichannel pipette should be used for best results. Leave at room temperature (18-25°C) and protected from direct sunlight for 20-25 minutes.

9. Stop the reaction by adding 100 μ L of Stop Solution to each well. The blue solution should change to a uniform yellow color. Ensure that the undersides of the wells are dry and that there are no air bubbles in the well contents.



10. Immediately after adding the Stop solution, read the absorbance values at 450 nm using a microtitration plate reader.

Interpretation of Results

Quantitative Analysis

Average the duplicate readings for each standard and sample, and subtract the average zero standard optical density (O.D.).

A 4-parameter logistic (4-PL) or a linear regression model providing a point-to-point curve fitting provides acceptable results. Create a standard curve by reducing the data using computer software capable of generating a four-parameter logistic (4-PL) or a linear regression curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. Do not force the line to be linear. The concentration of the specimens can be found directly from the standard curve.


Standards	450 nm absorbance
Standard 1 (50 ng/mL)	2.2772
Standard 2 (25 ng/mL)	1.2127
Standard 3 (12.5 ng/mL)	0.6851
Standard 4 (6.25 ng/mL)	0.3788
Standard 5 (3.125 ng/mL)	0.218
Standard 6 (1.56 ng/mL)	0.1448
Standard 7 (0.78 ng/mL)	0.1113
Standard 8 (0 ng/mL)	0.0654

Table 2. Example Data at 450nm.

Typical Human GFAP ELISA Kit Standard Curve

This standard curve was generated at OriGene for demonstration purpose only. A standard curve must be run with each assay.





Note: This standard curve is only an example and should not be used to generate any results.

Performance Characteristics

1. Recovery

The recovery of human GFAP spiked to three different-levels of the assay range in diluted samples was evaluated.

Sample	Average Recovery	Range
Hu Serum	98%	94%-101%
Hu EDTA Plasma	100%	97% -103%
Heparin Plasma	44%	42%-48%
Culture Media	109%	107%-111%

2. Linearity

To assess the linearity of the assay, human GFAP spiked samples were diluted to produce samples with values within the dynamic range of the assay.

		Serum	EDTA-plasma	Heparin-plasma	Culture Media
1:2	%Expected	111	106	107	99
1:4	%Expected	116	107	107	92
1:8	%Expected	106	89	96	82

3. Sensitivity: 85pg/mL



4. Precision

Three samples with different levels of GFAP were assayed 10 times each on three different assays. The intra-assay CV percentage and inter-assay CV percentage were calculated.

Sample	%CV in Assay 1	%CV in Assay 2	%CV in Assay 3	Ave %CV
Serum (n=10)	2.69	2.40	2.13	2.41
EDTA-Plasma (n=10)	1.46	2.08	2.18	1.91
Culture Media (n=10)	1.54	2.65	3.99	2.73

Sample	Mean (ng/ml) in assay1	Mean (ng/ml) in assay2	Mean (ng/ml) in assay3	Ave (ng/ml)	SD	%CV
Serum (n=10)	4.14	4.13	4.25	4.18	0.06	1.55
EDTA-Plasma (n=10)	4.70	4.85	4.83	4.79	0.08	1.69
Culture Media (n=10)	2.70	2.69	2.56	2.65	0.08	2.91

Limitations of Use

1. Assay values determined using assays from different manufacturers or different methods may not be used interchangeably.

2. The assay cannot be used to quantitate samples with GFAP assay values greater than the highest standard without further serial dilution of the samples. See the Interpretation of Results section for directions on testing such samples.

Contact Information: OriGene Technologies, Inc 9620 Medical Center Drive Rockville, MD 20850 Tel: 888.267.4436 Fax: 301.340.9254 Web: www.origene.com Version 03242022



Assay Flowchart

